February 28 (SeeNews) - German pharmaceutical company Boehringer Ingelheim (BI) plans to accelerate its investments in Turkey, Turkish media reported.
The company expects to produce half of the medicines in its human health portfolio in Turkey within the next five years, Sabah daily quoted BI Turkey general manager, Evren Ozlu as saying on Thursday.
BI Turkey branch recorded 50% growth in 2019, ahead of the average growth of 31.7% in the Turkish pharmaceutical market, Ozlu noted, citing data by IQVIA, a US-based provider of services to the pharmaceutical and healthcare industries.
The growth of the company in Turkey has boosted BI's operations in nearby markets, such as the Middle East and Africa, he said.